



## **MannKind Announces Data Presentation At 14th International Conference On Advanced Technologies & Treatments For Diabetes (ATTD 2021) To Be Held Virtually June 2-5**

June 3, 2021

### **Post hoc analysis of the STAT study shows that Technosphere® insulin reduced nocturnal hypoglycemia compared to insulin aspart in adult patients with T1D**

WESTLAKE VILLAGE, Calif., June 3, 2021 /PRNewswire/ -- MannKind Corporation (Nasdaq: MNKD), which focuses on the development of innovative medicines for patients with endocrine and orphan lung diseases, announced today that it will present a poster [Abstract #654 / Topic AS09 – New Insulin Delivery Systems: Inhaled, Transdermal, Implanted Devices] at the 14<sup>th</sup> International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2021) to be held virtually, June 2-5. The poster presents a post hoc analysis from the STAT study that demonstrates how Afrezza (Technosphere Insulin or TI) reduced nocturnal hypoglycemia compared to insulin aspart in adult patients with type 1 diabetes (T1D).



"When the STAT study was completed, it advanced our understanding of potential benefits of Afrezza for those living with Type 1 diabetes overall," said Dr. Kevin Kaiserman, Vice President, Medical Affairs and Safety of MannKind. "With this post hoc statistical analysis, we divided the CGM data into day and night and showed that using Technosphere Insulin versus aspart reduced Level 1 nocturnal hypoglycemia by 62% and Level 2 by 78%."

The ultra-rapid appearance and clearance of TI – which more closely mimics physiologic insulin compared with subcutaneous insulin aspart – may contribute to these findings, although larger studies are needed to confirm this hypothesis, Kaiserman explained.

The STAT study was a four-week, investigator-led, collaborative, open-label pilot study that included 60 patients with T1D on multiple daily injections of aspart who were randomized to either the control cohort using aspart (n=34) or the TI cohort (n=26). Level 1 (<70 mg/dL) and Level 2 (<54 mg/dL) hypoglycemia measures were obtained from continuous glucose monitors (CGM). For purposes of the study, nighttime was defined as 12 am to 6 am.

The poster is authored by Janet K. Snell-Bergeon, PhD; Halis K. Akturk, MD; Anne Peters, MD; Kevin Kaiserman, MD and Satish K. Garg – representing a collaboration between the Barbara Davis Center for Diabetes (University of Colorado-Aurora), Keck School of Medicine of USC, and MannKind.


#### **About MannKind Corporation**

MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA-approved product and the only inhaled ultra-rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. Afrezza is also available by prescription in Brazil, where it is commercialized by the Company's partner, Biomm SA. MannKind was established in 1991, and is headquartered in Westlake Village, Calif., with a manufacturing and R&D facility based in Danbury, Conn. The Company also employs field sales and medical representatives across the U.S. Please visit [mannkindcorp.com](http://www.mannkindcorp.com) to learn more.

### **Forward-looking Statements**

This press release contains forward-looking statements that involve risks and uncertainties. Words such as "believes", "anticipates", "plans", "expects", "intends", "will", "goal", "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon MannKind's current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, the risk that continued testing of Afrezza may not yield successful results or results that are consistent with earlier testing, and other risks detailed in MannKind's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2020 and subsequent periodic reports on Form 10-Q and current reports on Form 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.

AFREZZA and TECHNOSPHERE are registered trademarks of MannKind Corporation.

 View original content to download multimedia:<http://www.prnewswire.com/news-releases/mannkind-announces-data-presentation-at-14th-international-conference-on-advanced-technologies--treatments-for-diabetes-attd-2021-to-be-held-virtually-june-2-5-301304900.html>

SOURCE MannKind Corporation

Christie Iacangelo, Corporate Communications, (818) 292-3500, Email: [media@mannkindcorp.com](mailto:media@mannkindcorp.com), or Rose Alinaya, Investor Relations, (818) 661-5000, Email: [ir@mannkindcorp.com](mailto:ir@mannkindcorp.com)